Evaluation of Herbal Extracts of Momordica Charantia and Fenugreek Seeds for Management of Diabetes

The present study discloses a composition for regulating blood sugar levels, comprising a synergistic blend of Momordica Charantia extract, Fenugreek seed extract, and additional natural extracts. The composition offers a natural and holistic approach to blood sugar regulation, harnessing the potential benefits of these extracts to support glycemic control. Momordica Charantia extract, derived from the fruits of the Momordica Charantia plant, contains bioactive compounds such as charantin, polypeptide-p, and vicine. Fenugreek seed extract, obtained from Trigonella foenum graecum seeds, comprises soluble dietary fibers, saponins, and alkaloids, known for their potential in blood sugar regulation

Trading Electricity with Blockchain Systems

On the wave of the development of new ICT technologies and renewable energy, the power system will certainly experience great changes to its outdated architecture over the next several decades. One of the key drivers of change in the power system is distributed energy resources. They are completely changing the paradigm of the power system as a system with a centralized hierarchy and one-way power flows from generation to customer and from high voltage to low voltage. Because the goals of net zero greenhouse gas emissions are gathering pace and are being accepted by countries around the world, slowdown in the integration of distributed energy resources cannot be expected. Another reason why we can expect faster integration is the development of technology for energy production which is becoming more available to power consumers. Because of the problems that are currently occurring in the distribution system, it is clear that the system must be modernized in line with the development of these technologies. The technology that will likely have the greatest impact on the modernization of the power system is blockchain technology combined with the smart grid paradigm. Blockchain has the ability to completely change the way the power system is managed and optimized for performance

FRICTION STIR SURFACING OF COLD SPRAYED BAINITIC STEEL

A superficial composite layer was produced by friction stir surfacing (FSS) on high strength bainitic steel, cold sprayed with the Cu-Y2O3-ZrO2 and Zn-Y2O3-ZrO2 metal-oxide powders. The FSS resulted consolidation of the elemental powders in the cold sprayed (CS) layer with some melting of Zn and Cu. The formation of a continuous, adherent layer on the steel surface facilitates closing of large pores at the coating-substrate interface. The consolidated layer on the steel surface showed comminution of the coarse oxide particles and concomitant reduction in the average particle size. The FSS resulted in a composite layer consisting of the hard martensite structure up to 0.4 mm from the surface. The region just below the top solidified layer exhibited the soft ferrite and pearlite structure with narrow microstructural bands of fine martensite. The net torque and in-plane forces for the composite layer production are significantly different from the Zn and Cu cold sprayed layers

p40 & thyroid transcription factor-1 immunohistochemistry: A useful panel to characterize non-small cell lung carcinoma-not otherwise specified (NSCLC-NOS) category

Background & objectives: Accurate histopathological subtyping of non-small cell lung carcinoma (NSCLC) is essential for targeted therapeutic agents. Immunohistochemistry (IHC) is helpful in identification of different tumour subtypes. In this study two marker approaches, one each for glandular and squamous cell differentiation was applied to maximize the proportion of accurately subtyped NSCLC not otherwise specified (NOS) tumours on small biopsy samples. Methods: Two hundred and sixty three consecutive lung biopsies of primary lung carcinoma were prospectively studied. These were subtyped first morphologically and then by IHC for p40 and thyroid transcription factor-1 (TTF-1). The diagnosis of NSCLC-NOS before and after addition of IHC was evaluated. Results were correlated and validated with morphologically proven cases and matched surgical specimens. Results: Based on morphology, only 140 of the 263 (53.2%) cases of NSCLC were characterized, whereas 123 (46.7%) were classified as NSCLC-NOS type. With addition of IHC (p40 and TTF-1), the latter category reduced to 14.4 per cent and a sum of 225 (85.5%) cases were accurately subtyped into squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma. p40 showed 100 per cent sensitivity and specificity for squamous differentiation whereas TTF-1 showed sensitivity of 85.3 per cent and specificity of 98.1 per cent. Ninety per cent correlation of morphologic subtypes was achieved with matched resected specimens. Interpretation & conclusions: Our results showed that an approach of using only a two-antibody panel (p40 and TTF-1) might help in reduction of diagnostic category of NSCLC-NOS significantly and contribute in saving tissue for future molecular testing

Utility of conventional transbronchial needle aspiration with rapid on-site evaluation (c-TBNA-ROSE) at a tertiary care center with endobronchial ultrasound (EBUS) facility

Background: Conventional transbronchial needle aspiration (c-TBNA) is an underutilized bronchoscopic modality. Endobronchial ultrasound (EBUS) guided-TBNA though efficacious is an expensive modality, facilities of which are available at only limited centers. c-TBNA is cost-effective and has potential for wide utilization especially in resource-limited settings. Rapid on-site evaluation (ROSE) improves the yield of c-TBNA. Materials and Methods: A retrospective review of the bronchoscopy records (May 2012 to July 2014) was performed. The patients who underwent c-TBNA with ROSE were included in the study and their clinical details were extracted. Convex probe EBUS-TBNA was being regularly performed during the study period by the operators performing c-TBNA. Results: c-TBNA with ROSE was performed in 41 patients with mean age of 42.4 (16.2) years. The most frequently sampled node stations (>90% patients) were the subcarinal and lower right paratracheal. Representative samples could be obtained in 33 out of the 41 patients (80.4%). c-TBNA was diagnostic in 32 [tuberculosis (TB)-8, sarcoidosis-9, and malignancy-15] patients out of the 41 patients. The overall diagnostic yield (sensitivity) of c-TBNA with ROSE was 78%. Mean procedure duration was 18.4 (3.1) min and there were no procedural complications. Conclusion: c-TBNA with ROSE is a safe, efficacious, and cost-effective bronchoscopic modality. When it was performed by operators routinely performing EBUS-TBNA, diagnostic yields similar to that of EBUS-TBNA can be obtained. Even at the centers where EBUS facilities are available, c-TBNA should be routinely performed

Modifications of cell signalling and redox balance by targeting protein acetylation using natural and engineered molecules: implications in cancer therapy

Acetylation of proteins with the addition of an acetyl group on the lysine residue is one of the vital posttranslational modifications that regulate protein stability, function and intracellular compartmentalization. Like other posttranslational modifications, protein acetylation influences many if not all vital functions of the cell. Protein acetylation has been originally associated with histone acetylation regulated by Histone Acetyl Transferase (HAT) and Histone Deacetylase (HDAC) and was mainly considered to be involved in epigenetic regulation through chromatin remodelling. It is now widely referred to as lysine acetylation orchestrated by lysine acetyl transferase (KAT) and lysine deacetylase (KDAC) and influences many cellular functions. Protein acetylation fine tunes the redox balance and cell signalling in the context of cancer by exerting its control on expression of two very important redox sensors viz. Nrf2 and NF-kappa B. Accumulating evidences show that inhibitors of deacetylase (KDACi), responsible for cytotoxic effects in cancer cells, mediate their actions by inhibiting the deacetylases, thereby simulating an hyperacetylation state of histone as well as non-histone proteins, similar to the one created by KATs. Emergence of calreticulin (CRT) mediated protein acetylation system using polyphenolic acetates as donors coupled with over expression of CRT has opened new avenues for targeting protein acetylation for improving cancer therapy. Modifiers of protein acetylation are therefore, emerging as a class of anticancer therapeutics and adjuvant as they inhibit growth, induce differentiation and death (apoptosis) differentially in cancer cells and also exhibit chemo-radiation sensitizing potential. Although pre-clinical investigations with many natural and synthetic KDAC inhibitors have been very promising, their clinical utility has so far been limited to certain types of cancers of the hematopoietic system. The future of protein acetylation modifiers appears to depend on the development of newer engineered molecules and their rational combinations that can exploit the differences in the regulation of protein acetylation between tumor and normal cells/tissues